In inadequately controlled patients with Type 2 diabetes, Biphasic Insulin Aspart 30 combined with Pioglitazone provides better glycaemic control than Biphasic Insulin Aspart 30 monotherapy or Pioglitazone/Sulphonylurea combination.

被引：0
|
作者：
Raz, I
Stranks, S
Filipczak, R
Joshi, P
Lertoft, B
Råstam, J
Chow, FC
机构：
[1] Hadassah Hebrew Univ Hosp, Diabet Unit, Jerusalem, Israel
[2] Repatriat Gen Hosp, Daw Pk, Australia
[3] NZOZ Gadent, Diabet Unit, Rawa Mazowiecka, Poland
[4] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[5] Prince Wales Hosp, Diabet & Endocrine Ctr, Shatin, Hong Kong, Peoples R China
来源：
DIABETOLOGIA | 2003年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15
引用
收藏
页码：A8 / A8
页数：1
相关论文
共 50 条
  • [31] Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes
    Hermansen, K
    Colombo, M
    Storgaard, H
    Ostergaard, A
    Kolendorf, K
    Madsbad, S
    DIABETES CARE, 2002, 25 (05) : 883 - 888
  • [32] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    DIABETOLOGIA, 2018, 61 : S410 - S411
  • [33] Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study
    Gao, Y.
    Guo, X. H.
    Vaz, J. A.
    DIABETES OBESITY & METABOLISM, 2009, 11 (01): : 33 - 40
  • [34] Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
    Kilo, C
    Mezitis, N
    Jain, R
    Mersey, J
    McGill, J
    Raskin, P
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (06) : 307 - 313
  • [35] A Thrice Daily Regimen with Biphasic Insulin Aspart 50 Is More Effective and as Safe as Twice Daily Biphasic Insulin Aspart 30 in Chinese Subjects with Type 2 Diabetes
    Gao, Yan
    DIABETES, 2010, 59 : A153 - A153
  • [36] Better glycaemic control for 30,171 insulin-naive patients with type 2 diabetes after starting biphasic insulin aspart 30/70 (BIAsp 30) therapy:: IMPROVE™ study subgroup analysis
    Kawamori, R.
    Srishyla, M. V.
    Wenying, Y.
    DIABETOLOGIA, 2008, 51 : S393 - S394
  • [37] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
  • [38] Pharmacokinetics and glucodynamics of Biphasic Insulin Aspart 30 and 50 in Japanese Type 2 diabetes.
    Hirao, K
    Maeda, H
    Urata, S
    Takisawa, Y
    Hirao, S
    Kageyama, S
    DIABETOLOGIA, 2003, 46 : A269 - A270
  • [39] Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations
    Akalin, Sema
    Aydin, Hasan
    Balci, Mustafa Kemal
    Comlekci, Abdurrahman
    Dinccag, Nevin
    Erbas, Tomris
    Ersoz, Halil Onder
    Yavuz, Dllek Gogas
    Gullu, Sevim
    Sahin, Ibrahim
    Siva, Zeynep Oscar
    Unluhizarci, Kursad
    TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2018, 22 (03) : 183 - 197
  • [40] Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes
    Valentine, William J.
    Pollock, Richard F.
    Plun-Favreau, Juliette
    White, Jeremy
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1399 - 1412
12345